Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
The investigation of the molecular mechanisms involved in carcinogenesis and tumor progression has led to the development of numerous biochemical markers. Biochemical markers may serve for early prediction of tumor recurrence, progression and development of metastases including bone metastases and for prediction of response to therapy. Tumor antigens have been used for more than a decade and although they have shown promising clinical results, their sensitivity and specificity remain limited. A lot of knowledge on the key molecules which control cell cycle, apoptosis and angiogenesis has been acquired during recent years, but their clinical value remains uncertain. Molecular markers which are linked to malignant transformation may provide a non-surgical therapeutic approach by targeting these molecules through gene therapy or antisense molecules. Because of the complexity of the physiopathogical processes involved in tumorogenesis and metastases, we first provide a review on the molecular basis of the various tumor markers and then discuss their potential clinical utility for the major cancers. The review of the current literature indicates that at the exception of a few examples, such as the use of Her-2 to predict response of the targeted Herceptin therapy, no single marker is sensitive and specific enough to perform an accurate diagnosis, predict disease progression or response to treatment. A combination of different biochemical and imaging markers appears to be the most promising strategy to monitor patients with cancer.
Voorzanger-Rousselot
N
N
Molecular Markers, SYNARC, 16 rue Montbrillant, Le Buroparc T4, Lyon Cedex 03, France.
Garnero
P
P
D014408:Biomarkers, Tumor / Q000032:analysis*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D008297:Male; D008403:Mass Screening; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009369:Neoplasms / Q000175:diagnosis*; D009389:Neovascularization, Pathologic / Q000175:diagnosis; D011379:Prognosis; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D014408:Biomarkers, Tumor